United Kingdom signs supply deal with Sanofi, GSK for virus vaccine

The government has signed a deal for up to 60 million potential coronavirus vaccines. File pic

The government has signed a deal for up to 60 million potential coronavirus vaccines. File pic

A major portion of the aggregate global supply of the vaccine is thus likely to be entitled to the ACT (Access to COVID‐19 Tools) Accelerator, which is a global initiative by leading governments, health organizations, and philanthropies around the world to speed up the development of effective COVID-19 treatments and vaccines.

The Government has stressed the importance of investing in a broad range of vaccines, to improve the chances of a successful outcome.

Human medical scientific tests of the vaccine will start in September followed by a section 3 research in December.

Kate Bingham, chair of the U.K.'s Vaccines Taskforce, said through the agreement with GSK and Sanofi, the Vaccine Taskforce can add another type of vaccine to the three different types of vaccine it has already secured.

The first people to get the vaccine will be frontline heath and social care workers, the elderly and the most vulnerable.

"The point stays we may perhaps under no circumstances get a vaccine and, if we do get one particular, we have to be well prepared that it may well not be a vaccine which helps prevent acquiring the virus, but rather just one that decreases signs and symptoms".

Britain previously secured access to 30 million doses of the experimental BioNTech/Pfizer vaccine, and another deal for 60 million doses of the potential Valneva vaccine.

A deal has also been agreed to secure access to treatments containing COVID-19 neutralising antibodies from AstraZeneca, to protect those who can not receive vaccines such as cancer and immunocompromised patients.

Russia Plans to Register World's First Coronavirus Vaccine By August
The adenoviral vector-based vaccine developed by Russian military and government researchers is now in phase 2 trials. News about the planned approval of the vaccine comes as global confirmed cases of coronavirus hit 16,747,268.

That adopted a earlier announced pact with AstraZeneca for output of 100 million doses of its potential vaccine, remaining created in partnership with Oxford College.

The UK Government will secure supplies for the whole of the UK.

With no working vaccine against COVID-19 yet developed, Britain now has 250 million doses potentially available.

While there is no fully tested coronavirus vaccine out yet, the United Kingdom government has invested in four different trials, all of which look promising. Both companies are allegedly intent on making their vaccine affordable and available to people worldwide.

Pfizer and BioNTech COVID-19 vaccine candidate enters Phase II/III trials...

Emma Walmsley, chief executive, said: "As expected, our performance this [second] quarter was disrupted by COVID-19, particularly in our Vaccines business, as visits to healthcare professionals were limited due to lockdown measures".

What are the COVID-19 vaccine contenders? As well as age and underlying co-morbid conditions, the committee notes that early signals have been identified of other potential risk factors, including deprivation and ethnicity.

Recommended News

We are pleased to provide this opportunity to share information, experiences and observations about what's in the news.
Some of the comments may be reprinted elsewhere in the site or in the newspaper.
Thank you for taking the time to offer your thoughts.